Scancell (LON:SCLP) Hits New 1-Year High – Time to Buy?

Scancell Holdings plc (LON:SCLP)’s stock price hit a new 52-week high during mid-day trading on Friday . The stock traded as high as GBX 14 and last traded at GBX 13.39, with a volume of 1346237 shares traded. The stock had previously closed at GBX 13.50.

Scancell Stock Down 0.8%

The company’s 50-day moving average price is GBX 12.16 and its 200 day moving average price is GBX 10.63. The company has a debt-to-equity ratio of -566.79, a quick ratio of 13.01 and a current ratio of 3.42. The stock has a market cap of £138.96 million, a PE ratio of -24.35 and a beta of 0.35.

Scancell (LON:SCLP) last posted its quarterly earnings data on Thursday, January 29th. The company reported GBX (0.55) earnings per share (EPS) for the quarter. As a group, analysts forecast that Scancell Holdings plc will post -2.5361112 EPS for the current fiscal year.

Scancell Company Profile

Scancell (LSE:SCLP) is a clinical stage company leveraging two proprietary platforms, Immunobody® and Moditope®, to develop targeted off-the-shelf, patient-accessible active immunotherapies for a cancer-free future. The lead product iSCIB1+ is an Immunobody® DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. When combined with checkpoint therapies it showed additional clinical benefit over the checkpoints (CPI) alone in the ongoing Phase 2 SCOPE trial in advanced melanoma.